IFNG and melanoma: The inhibition of methyltransferase 3, N6-adenosine-methyltransferase complex catalytic subunit (METTL3) enhances the response to anti-PD-1 therapy in melanoma by stabilizing the IFN-γ/STAT1/IRF1 pathway [122].